• Atai Beckley dosed the last patient in its Phase 2b Elumina trial of VLS-01 for treatment-resistant depression.
• Topline data are expected in Q4 2026, setting up a potential inflection point for the program’s next-stage development.
• The study randomized 156 patients in a double-blind, placebo-controlled design, with the primary endpoint at Day 29 on MADRS.
• Phase 3 development in major depressive disorder is planned if Phase 2 results are supportive, with generalized anxiety disorder flagged as a follow-on.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atai Beckley Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060600PRIMZONEFULLFEED9757224) on July 06, 2026, and is solely responsible for the information contained therein.